Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 3
2017 1
2019 4
2020 2
2021 2
2022 13
2023 23
2024 13
2025 19
2026 18

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

86 results

Results by year

Filters applied: . Clear all
Page 1
Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.
Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, Germino R, Menon S, Sun Y, Wang C, Shapiro AB, Kanik KS, Connell CA; ORAL Surveillance Investigators. Ytterberg SR, et al. N Engl J Med. 2022 Jan 27;386(4):316-326. doi: 10.1056/NEJMoa2109927. N Engl J Med. 2022. PMID: 35081280 Clinical Trial.
METHODS: We conducted a randomized, open-label, noninferiority, postauthorization, safety end-point trial involving patients with active rheumatoid arthritis despite methotrexate treatment who were 50 years of age or older and had at least one additional cardiovascular …
METHODS: We conducted a randomized, open-label, noninferiority, postauthorization, safety end-point trial involving patients with active rhe …
Cardiovascular and Venous Thromboembolic Risk With JAK Inhibitors in Immune-Mediated Inflammatory Skin Diseases: A Systematic Review and Meta-Analysis.
Ingrassia JP, Maqsood MH, Gelfand JM, Weber BN, Bangalore S, Lo Sicco KI, Garshick MS. Ingrassia JP, et al. JAMA Dermatol. 2024 Jan 1;160(1):28-36. doi: 10.1001/jamadermatol.2023.4090. JAMA Dermatol. 2024. PMID: 37910098 Free PMC article.
IMPORTANCE: Janus kinase (JAK) inhibitors are an effective treatment option for patients with certain skin-related conditions, such as atopic dermatitis, alopecia areata, and vitiligo, but there is a current US Food and Drug Administration (FDA) boxed …
IMPORTANCE: Janus kinase (JAK) inhibitors are an effective treatment option for patients with certain skin-relat …
Cardiovascular risk and JAK inhibitor for the treatment of spondyloarthritis: A systematic review.
Dhahri R, Ben Ammar L, Boussaid S, Bellakhal S, Gharsallah I, Sahli H, Douggui MH. Dhahri R, et al. Tunis Med. 2025 Sep 9;103(9):1202-1209. doi: 10.62438/tunismed.v103i9.6218. Tunis Med. 2025. PMID: 41848136 Free article.
OBJECTIVE: The aim of this review is to evaluate cardiovascular safety of Janus Kinas (JAK) inhibitors in patients with spondyloarthritis (SpA). METHODS: Applying the PRISMA methodology, we searched PubMed, Embase, and the Cochrane Library databases us …
OBJECTIVE: The aim of this review is to evaluate cardiovascular safety of Janus Kinas (JAK) inhibitors in patien …
Cardiovascular risk and JAK inhibitor for the treatment of spondyloarthritis: A systematic review protocol.
Dhahri R, Bellakhal S, Boussaid S, Ben Ammar L, Bettaieb H, Gharsallah I, Sahli H, Douggui MH. Dhahri R, et al. Tunis Med. 2025 Aug 1;103(8):975-977. doi: 10.62438/tunismed.v103i8.5613. Tunis Med. 2025. PMID: 41832663 Free article.
The aim of this review is to evaluate cardiovascular safety of JAK inhibitors. METHODS: We will search multiple databases, including PubMed, Embase, and the Cochrane Library, using specific keywords such as "Janus kinase inhibitors," " …
The aim of this review is to evaluate cardiovascular safety of JAK inhibitors. METHODS: We will search multiple databas …
Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance.
Charles-Schoeman C, Buch MH, Dougados M, Bhatt DL, Giles JT, Ytterberg SR, Koch GG, Vranic I, Wu J, Wang C, Kwok K, Menon S, Rivas JL, Yndestad A, Connell CA, Szekanecz Z. Charles-Schoeman C, et al. Ann Rheum Dis. 2023 Jan;82(1):119-129. doi: 10.1136/ard-2022-222259. Epub 2022 Sep 22. Ann Rheum Dis. 2023. PMID: 36137735 Free PMC article. Clinical Trial.
OBJECTIVES: Evaluate risk of major adverse cardiovascular events (MACE) with tofacitinib versus tumour necrosis factor inhibitors (TNFi) in patients with rheumatoid arthritis (RA) with or without a history of atherosclerotic cardiovascular di …
OBJECTIVES: Evaluate risk of major adverse cardiovascular events (MACE) with tofacitinib versus tumour necrosis factor …
Risk of Major Adverse Cardiovascular Events and Venous Thromboembolism with JAK Inhibitors versus TNF Inhibitors in Rheumatoid Arthritis Patients: A Systematic Review and Meta-Analysis.
Partalidou S, Patoulias D, Deuteraiou K, Avgerou P, Kitas G, Tzitiridou-Chatzopoulou M, Dimitroulas T. Partalidou S, et al. Mediterr J Rheumatol. 2024 Mar 30;35(Suppl 1):10-19. doi: 10.31138/mjr.171023.rof. eCollection 2024 Mar. Mediterr J Rheumatol. 2024. PMID: 38756933 Free PMC article.
OBJECTIVE: The aim of this study was to compare the risk of major cardiovascular events (MACE) and venous thromboembolic events (VTE) between tumour necrosis factor (TNF) and Janus kinase (JAK) inhibitors in patients with rheumatoi …
OBJECTIVE: The aim of this study was to compare the risk of major cardiovascular events (MACE) and venous thromboemboli …
Risk of Major Adverse Cardiovascular Events and Thromboembolism Events in Patients with Psoriatic Arthritis on JAK Inhibitors: A Network Meta-Analysis.
Shi LH, Wei JC, Tung WT. Shi LH, et al. Rheumatol Ther. 2025 Oct;12(5):799-813. doi: 10.1007/s40744-025-00783-5. Epub 2025 Jul 19. Rheumatol Ther. 2025. PMID: 40684063 Free PMC article. Review.
OBJECTIVES: Our objective was to evaluate the comparative effects of five Janus kinase inhibitors (JAKis) with ten interventions, comparing their impact on major adverse cardiovascular events (MACE) and thromboembolism events (TE) in patients wi …
OBJECTIVES: Our objective was to evaluate the comparative effects of five Janus kinase inhibitors (JAKis) with ten inte …
Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b/4 randomised safety study.
Buch MH, Bhatt DL, Charles-Schoeman C, Giles JT, Mikuls T, Koch GG, Ytterberg S, Nagy E, Jo H, Kwok K, Connell CA, Masri KR, Yndestad A. Buch MH, et al. RMD Open. 2024 Apr 12;10(2):e003912. doi: 10.1136/rmdopen-2023-003912. RMD Open. 2024. PMID: 38609322 Free PMC article. Clinical Trial.
METHODS: Patients with RA aged 50 years and with 1 additional CV risk factor received tofacitinib 5 mg or 10 mg two times per day or TNFi. MACE (non-fatal myocardial infarction (MI), non-fatal stroke or CV death (MACE-3)) was extended by sequential addition …
METHODS: Patients with RA aged 50 years and with 1 additional CV risk factor received tofacitinib 5 mg or 10 mg two times per day o …
Comparative Safety of Janus Kinase Inhibitors vs Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases.
Ahuja D, Yeh KH, Patel SB, Lee HH, Goodwin SW, Solitano V, Ma C, Ananthakrishnan AN, Singh N, Jairath V, Xu R, Singh S. Ahuja D, et al. Clin Gastroenterol Hepatol. 2026 Mar;24(3):794-804. doi: 10.1016/j.cgh.2025.06.041. Epub 2025 Jul 28. Clin Gastroenterol Hepatol. 2026. PMID: 40738278 Free PMC article.
BACKGROUND & AIMS: We conducted a retrospective cohort study comparing the safety of Janus kinase (JAK) inhibitors vs tumor necrosis factor-a (TNF) antagonists in patients with inflammatory bowel diseases (IBDs). ...CONCLUSIONS: In an observational …
BACKGROUND & AIMS: We conducted a retrospective cohort study comparing the safety of Janus kinase (JAK) inhibito …
Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme.
Fleischmann R, Curtis JR, Charles-Schoeman C, Mysler E, Yamaoka K, Richez C, Palac H, Dilley D, Liu J, Strengholt S, Burmester G. Fleischmann R, et al. Ann Rheum Dis. 2023 Sep;82(9):1130-1141. doi: 10.1136/ard-2023-223916. Epub 2023 Jun 12. Ann Rheum Dis. 2023. PMID: 37308218 Free PMC article. Clinical Trial.
OBJECTIVE: Increased risk of serious adverse events (AEs) was reported for tofacitinib relative to tumour necrosis factor inhibitor therapy in patients with rheumatoid arthritis (RA) aged 50 years enriched for cardiovascular (CV) risk (ORAL Surveillan …
OBJECTIVE: Increased risk of serious adverse events (AEs) was reported for tofacitinib relative to tumour necrosis factor inhibito …
86 results